Patents Assigned to Claragen, Inc. and U.S. Government
  • Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
    Patent number: 6255281
    Abstract: Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: July 3, 2001
    Assignee: Claragen, Inc. and U.S. Government
    Inventors: Aprile L. Pilon, Anil B. Mukherjee, Zhongjian Zhang